CNS PHARMACEUTICALS, INC. (CNSP): Price and Financial Metrics
GET POWR RATINGS... FREE!
CNSP Stock Price Chart Interactive Chart >
CNSP Price/Volume Stats
| Current price | $1.00 | 52-week high | $13.43 |
| Prev. close | $0.99 | 52-week low | $0.95 |
| Day low | $0.95 | Volume | 74,100 |
| Day high | $1.06 | Avg. volume | 45,792 |
| 50-day MA | $1.73 | Dividend yield | N/A |
| 200-day MA | $4.82 | Market Cap | 13.29M |
CNS PHARMACEUTICALS, INC. (CNSP) Company Bio
CNS Pharmaceuticals, Inc. is a preclinical stage pharmaceutical company, which engages in the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. Its product pipeline includes berubicin, and CNS-12. The company was founded by Waldemar Priebe in July 2017 and is headquartered in Houston, TX.
Latest CNSP News From Around the Web
Below are the latest news stories about CNS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate CNSP as an investment opportunity.
CNS Pharmaceuticals to Present at the Virtual Investor GBM Spotlight EventCNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that it will present at the Virtual Investor GBM Spotlight Event on Tuesday, April 4, 2023 at 3:00 PM ET. |
CNS Pharmaceuticals Announces it Has No Exposure to Silicon Valley Bank IssuesCNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that it is aware that the Federal Deposit Insurance Corp. has taken control of Silicon Valley Bank ("SVB") due to liquidity concerns. The Company does not hold any deposits or investments at SVB. |
CNS Pharmaceuticals Continues Momentum in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM with First Patient Enrolled in SwitzerlandCNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that the first patient in Switzerland has been enrolled in the Company's ongoing potentially pivotal global trial evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. |
CNS Pharmaceuticals Announces First Patient Enrolled in Spain in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBMCNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that the first patient in Spain has been enrolled in the Company's ongoing potentially pivotal global trial evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. |
CNS Pharmaceuticals Announces Investigator-Initiated Phase 1b/2 Trial to be Conducted at the Pomeranian Medical University in PolandCNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced an investigator-initiated Phase 1b/2 trial evaluating the Company's novel anthracycline, Berubicin, which will be conducted at the Pomeranian Medical University (PUM) in Szczecin, Poland. |
CNSP Price Returns
| 1-mo | -45.95% |
| 3-mo | -58.33% |
| 6-mo | -81.38% |
| 1-year | -90.28% |
| 3-year | -98.41% |
| 5-year | N/A |
| YTD | -58.33% |
| 2022 | -88.61% |
| 2021 | -60.54% |
| 2020 | -54.94% |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...